Heterocyclic Compounds

Matches 301 - 350 out of 15,392	< 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 >

Document	Document Title
WO/2023/122938A1	HETEROCYCLIC COMPOUNDS AS SHP2 INHIBITORS, COMPOSITIONS COMPRISING THE HETEROCYCLIC COMPOUND, AND METHODS OF USE THEREOF Disclosed herein are compounds of formula (I), and/or a stereoisomer, a stable isotope, or a pharmaceutically acceptable salt or solvate thereof; and therapeutic uses of these compounds, which are inhibitors of SHP2, potentially useful i...
WO/2023/125102A1	METHOD FOR SYNTHESIZING 1H-FURO[3,2-B]IMIDAZO[4,5-D]PYRIDINE COMPOUND The present invention provides a method for synthesizing a 1H-furo[3,2-b]imidazo[4,5-d]pyridine compound, the method comprising the following steps: reacting a compound 1 with a compound 2 in a solvent in the presence of a base to obtain...
WO/2023/130054A2	HETEROARYL COMPOUNDS AS INHIBITORS OF IRAK4, COMPOSITIONS AND APPLICATIONS THEREOF The present disclosure relates to the field of medicinal chemistry, and specifically relates to a compound with interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitory activity, and pharmaceutical compositions and applications ther...
WO/2023/125707A1	P38 MAPK/MK2 PATHWAY REGULATOR, COMPOSITION THEREOF, PREPARATION METHOD THEREFOR AND USE THEREOF Disclosed in the present disclosure are a compound as shown in formula I, a racemate, a stereoisomer, a tautomer, an isotope label, a solvate, a pharmaceutically acceptable salt or a prodrug thereof, and a composition thereof, a preparat...
WO/2023/122859A1	S-(+)-PRANOPROFEN DERIVATIVE, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF Disclosed are an S-(+)-pranoprofen derivative, a preparation method therefor, a pharmaceutical composition thereof, and a use thereof. The provided S-(+)-pranoprofen derivative has excellent salt formability, so that solubility is improv...
WO/2023/120062A1	ELECTRONIC BARRIER MATERIAL AND ORGANIC SEMICONDUCTOR ELEMENT This compound represented by the general formula below is useful as an electron barrier material. R1-R21 each represent H, a deuterium atom, and a substituent other than a cyano group, and X represents O or S.
WO/2023/120696A1	1H-PYRAZOLE-3-AMINE DERIVATIVE HAVING BICYCLIC BACKBONE The present invention provides a compound that exhibits an anticancer effect based on Checkpoint Kinase 1 (CHK1) inhibition. It is discovered that a compound represented by formula (1) or a pharmaceutically acceptable salt thereof has a ...
WO/2023/116390A1	PYRIMIDINE-2(1H)-ONE-FUSED BICYCLIC COMPOUND HAVING MAT2A INHIBITORY ACTIVITY AND USE THEREOF Provided are a pyrimidine-2(1H)-one-fused bicyclic compound having an MAT2A inhibitory activity and the use thereof. Specifically, provided are a compound of formula (I) having an MAT2A inhibitory activity, a stereoisomer thereof, a phar...
WO/2023/115142A1	ARYLSULPHONAMIDE COMPOUNDS This invention relates to compounds of formula (I) and salts, solvates, tautomers, N-oxides, stereoisomers, polymorphs and/or prodrugs thereof. Also disclosed is the use of the compounds of formula (I) to treat necroptosis and/or inhibit...
WO/2023/122140A1	PARP1 INHIBITORS The present disclosure provides compounds, compositions, and methods useful for inhibiting PARP1, and/or treating a disease, disorder, or condition associated with PARP1, and/or treating cancer.
WO/2023/122662A1	COVALENTLY BINDING INHIBITORS OF G12S, G12D AND/OR G12E MUTANTS OF K-RAS GTPASE Described herein, inter alia, are GTPase inhibitors and uses thereof.
WO/2023/115166A1	COMPOUNDS The present disclosure relates generally to compounds, their methods of synthesis, and their use in the treatment of mental illness or central nervous system disorders.
WO/2023/116884A1	CDK2 INHIBITORS AND USE THEREOF The present disclosure provides a compound represented by structural formula (I) : or a pharmaceutically acceptable salt, or a stereoisomer thereof and their use in, e.g. treating a disease or disorder associated with CDK2. This disclosu...
WO/2023/116822A1	SOLID FORMS OF A TYK2 INHIBITOR, METHOD OF PREPARATION, AND USE THEREOF Disclosed herein are a solid Form of a TYK2 inhibitor N- (5- (2, 2-dimethyl-2, 3-dihydro- [1, 4] dioxino [2, 3-b]pyridin-6-yl) -4- ( (6- (methylsulfonyl) -4- (tetrahydro-2H-pyran-4-yl) pyridin-2-yl) amino) pyridin-2-yl) acetamide per se ...
WO/2023/121413A1	NOVEL BICYCLIC HETEROCYCLYL COMPOUND AND USE THEREOF The present invention relates to: a novel bicyclic heterocyclyl compound which has an SOS1 inhibitory activity and thus may be utilized for preventing, relieving or treating various carcinomas or RASopathy; a stereoisomer thereof; a solv...
WO/2023/120452A1	SREBP-1 INHIBITOR AND PHARMACEUTICAL COMPOSITION FOR TREATING HYPERTRIGLYCERIDEMIA This SREBP-1 inhibitor has inhibitory activity against SREBP-1 and does not have inhibitory activity against SREBP-2, the SREBP-1 inhibitor containing, as an active ingredient, one or more compounds from among compounds represented by fo...
WO/2023/122260A2	INHIBITORS OF SARS-COV-2 Described herein are compounds, and methods for the treatment of coronavirus infection.
WO/2023/119098A1	PROTEIN KINASE C THETA INHIBITORS The present invention relates to PKCθ inhibitors of formula I and pharmaceutically acceptable salts thereof and uses of such compounds. Compound uses include inhibiting PKCθ activity in a subject in need of such treatment, treating T-c...
WO/2023/115203A1	OXER1 ANTAGONISTS AND USES THEREOF Disclosed are compounds of formula (I), wherein ring A is an 8-10 membered aromatic or partially aromatic bicyclic ring having 1-4 heteroatoms compositions thereof, wherein L1, L2, R1 to R4 and m are as defined in claim 1; and methods of...
WO/2023/114954A1	PYRAZOLOPYRAZINE COMPOUNDS AS SHP2 INHIBITORS Provided herein are compounds and pharmaceutical compositions thereof for modulating SHP2 and their use in the treatment of disease.
WO/2023/111799A1	PYRIDINE-3-CARBOXYLATE COMPOUNDS AS CaV1.2 ACTIVATORS The present disclosure provides for a compound according to formula (I) or a pharmaceutically acceptable salt thereof as Cav1.2 activators for the treatment of schizophrenia, bipolar disorder, major depressive disorder, substance use dis...
WO/2023/115002A1	ANALOGS OF 4-BROMO-2,5-DIMETHOXYPHENETHYLAMINE The present disclosure relates to compound Formula (I) methods for making the compounds and methods for their use.
WO/2023/111996A1	COMPOSITIONS AND METHODS OF MAKING AND USING SMALL MOLECULES IN THE TREATMENT OF CANCER Embodiments of the instant disclosure relate to novel compounds, compositions, and methods for treating health conditions. In certain embodiments, methods of treating cancers can include administering an effective amount of at least one ...
WO/2023/110664A1	HERBICIDAL PYRIDONE DERIVATIVES Compounds of Formula (I) wherein the substituents are as defined in claim 1. The invention further relates to herbicidal compositions which comprise a compound of Formula (I) and to the use of compounds of Formula (I) for controlling wee...
WO/2023/114858A1	BENZOFURAN AND BENZOTHIOPHENE PSYCHOPLASTOGENS AND USES THEREOF Disclosed herein are compounds, compositions, and methods for promoting neuronal growth and/or improving neuronal structure with the compounds and compositions disclosed herein. Also described are methods of treating diseases or disorder...
WO/2023/110700A1	DIHYDROFUROPYRIDINE DERIVATIVES AS RHO-KINASE INHIBITORS The invention relates to compounds of formula (I) inhibiting Rho Kinase that are dihydrofuropyridine derivatives, methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. Particularly ...
WO/2023/109965A1	CAMPTOTHECIN COMPOUND AND CONJUGATE THEREOF Provided is a camptothecin compound, which is a compound represented by structural formula I or a pharmaceutically acceptable salt, stereoisomer, solvate or prodrug thereof. An antibody-drug conjugate comprising the camptothecin compound...
WO/2023/114822A1	BENZOTHIAZOLE, BENZOISOXAZOLE AND BENZODIOXOLE ANALOGS AS RXFP1 RECEPTOR AGONISTS The disclosure relates to compounds of Formula (I), which are RXFP1 receptor agonists, compositions containing them, and methods of using them, for example, in the treatment of heart failure, fibrotic diseases, and related diseases such ...
WO/2023/110394A1	PROCESS FOR C-H INSERTION BY GEM-HYDROGENATION OF AN INTERNAL ALKYNE The present invention is directed to a process for C-H insertion by the gem-hydrogenation of an internal alkyne.
WO/2023/109471A1	SPIRO PYRIMIDINONE DERIVATIVE, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF Provided are a compound as represented in general formula (I), and a cis-trans isomer, an enantiomer, a diastereoisomer, a racemate, a solvate, a hydrate or a pharmaceutically acceptable salt or a precursor drug thereof, and a preparatio...
WO/2023/114539A1	AMINO CHROMEN-2-ONE MODULATORS OF POLRMT The present invention provides novel amino chromen-2-one compounds that are inhibitors of mitochondrial RNA polymerase for treating various diseases such as cancer and others associated with metabolic disorders and mitochondrial dysfunct...
WO/2023/114428A1	HETEROCYCLE DERIVATIVES FOR THE TREATMENT OF DISEASE The disclosure provides heterocycle derivatives of Formula (I) for the inhibition of the oligosaccharyltransferase complex and the treatment of disease.
WO/2023/104051A1	COMBINED USE OF INDOLE SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUND AND STATIN COMPOUND Disclosed is the combined use of an indole substituted tetrahydroisoquinoline compound and a statin compound. Specifically, a safe and non-interaction pharmaceutical composition or pharmaceutical combination. The composition contains an ...
WO/2023/107722A1	COMPOUNDS FOR USE IN TREATING NEUROLOGICAL DISORDERS This disclosure provides compounds of formula (I) and pharmaceutically acceptable salts thereof, that inhibit Dual specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A). These chemical entities are useful, e.g., for treating ...
WO/2023/107356A1	ANTIMALARIAL AGENTS The present invention provides methods of treating malaria comprising administration of compounds of Formula (I) or a pharmaceutically acceptable salt thereof, to a subject in need thereof, wherein the variables are as defined herein. Th...
WO/2023/107606A1	BCL-XL/BCL-2 DUAL DEGRADERS FOR TREATMENT OF CANCERS Provided herein are compounds (e.g., compounds of Formula (I) or Formula (II)), their mechanism of action, and methods of modulating proliferation activity, and methods of treating diseases and disorders using the compounds provided here...
WO/2023/104178A1	PROTEIN KINASE INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF A series of compounds for regulating activity of a protein kinase, in particular a compound for inhibiting activity of PLK1. Further provided are a pharmaceutical composition containing the compound, and a use of the compound and the pha...
WO/2023/104213A1	CYCLIC BISBENZYL TETRAHYDROISOQUINOLINE COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF The present invention provides a cyclic bisbenzyl tetrahydroisoquinoline compound as represented by formula (I), and a pharmaceutically acceptable salt, an enantiomer, a diastereoisomer, a racemate, a crystalline hydrate, and a solvate t...
WO/2023/106625A1	HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME The present invention relates to: a heterocyclic compound represented by chemical formula 1; and an organic light-emitting device comprising same.
WO/2023/099072A1	COMPOUNDS Compounds of formula (I) wherein Y, n, R1, R2 and R3 have the meanings indicated herein, or a pharmaceutically acceptable solvate or salt thereof, are disclosed. The compounds are useful as inhibitors of protein or lipid kinases (in part...
WO/2023/102162A1	TGONOVEL HDAC INHIBITORS AND THERAPEUTIC USE THEREOF Described herein are novel compounds, compositions and methods for treatment of diseases including cancer using such compounds, compositions, and methods. The compounds include those of Formula (I):
WO/2023/098515A1	METHOD FOR PREPARING DRUG-LINKER CONJUGATE Provided in the present application is a method for preparing a drug-linker conjugate. Specifically, provided in the present application is a method for preparing compound IM2, the method comprising the following steps: adding compound S...
WO/2023/102378A1	MACROCYCLIC COMPOUNDS HAVING FARNESYLTRANSFERASE INHIBITORY ACTIVITY The present invention relates to macrocyclic compounds of any one of Formula (I), or a pharmaceutically acceptable form thereof, pharmaceutical compositions comprising the same, methods of preparing the same, and methods of treating canc...
WO/2023/101981A1	SPIROCYCLIC INHIBITORS OF APOL1 AND METHODS OF USING SAME The disclosure provides at least one compound, tautomer, deuterated derivative, or pharmaceutically acceptable salt chosen from compounds of Formula I, tautomers thereof, deuterated derivatives of those compounds or tautomers, and pharma...
WO/2023/102228A1	HETEROCYCLIC COMPOPUNDS AS GCN2 AND PERK KINASE INHIBITORS Described herein are compounds of Formula l-A that are inhibitors of GCN2 kinase or PERK kinase, and methods of treating diseases, including diseases associated with GCN2 kinase or PERK kinase, with said compounds.
WO/2023/102231A1	5-PYRIMIDINECARBOXAMIDE DERIVATIVES AND METHODS OF USING THE SAME The present disclosure relates to compounds of Formula (I): and to their prodrugs, pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds of the present disclosure...
WO/2023/097194A2	THERAPEUTIC COMPOUNDS AND METHODS OF USE This disclosure relates to compounds and methods of using said compounds, as well as pharmaceutical compositions containing such compounds, for treating diseases and conditions mediated by TEAD, such as cancer.
WO/2023/094304A1	MICROBIOCIDAL HETEROBIARYL AMIDE DERIVATIVES Compounds of Formula (I), wherein the substituents are as defined in claim 1, useful as pesticides, especially as fungicides.
WO/2023/096225A1	HETEROCYCLIC COMPOUND, AND ORGANIC LIGHT-EMITTING DEVICE AND COMPOSITION FOR FORMING ORGANIC MATERIAL LAYER, COMPRISING SAME The present specification relates to a heterocyclic compound of chemical formula 1, and an organic light-emitting device and a composition for forming an organic material layer, comprising same.
WO/2023/097204A1	MICROSPHERE FORMULATIONS COMPRISING ASENAPINE AND METHODS FOR MAKING AND USING THE SAME Microsphere formulations comprising asenapine are provided. Methods for making and using the microsphere formulations are also provided.

Matches 301 - 350 out of 15,392	< 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 >